1. Home
  2. QCLS vs GDTC Comparison

QCLS vs GDTC Comparison

Compare QCLS & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QCLS

Q/C Technologies Inc.

N/A

Current Price

$3.85

Market Cap

27.6M

Sector

Health Care

ML Signal

N/A

Logo CytoMed Therapeutics Limited

GDTC

CytoMed Therapeutics Limited

HOLD

Current Price

$1.05

Market Cap

12.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QCLS
GDTC
Founded
2014
2018
Country
United States
Singapore
Employees
2
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.6M
12.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
QCLS
GDTC
Price
$3.85
$1.05
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
818.8K
27.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$5.37
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$0.73
52 Week High
$8.17
$3.68

Technical Indicators

Market Signals
Indicator
QCLS
GDTC
Relative Strength Index (RSI) 47.96 44.40
Support Level $3.42 $0.96
Resistance Level $3.86 $1.25
Average True Range (ATR) 0.40 0.06
MACD 0.03 0.00
Stochastic Oscillator 26.73 43.53

Price Performance

Historical Comparison
QCLS
GDTC

About QCLS Q/C Technologies Inc.

Q/C Technologies Inc is engaged in building blockchain infrastructure that is faster and more energy-efficient. The company uses laser-based processors inspired by quantum technology that can solve complex problems at the speed of light. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.

About GDTC CytoMed Therapeutics Limited

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Share on Social Networks: